Nurix Therapeutics stock hits 52-week low at $13.64 By Investing.com
Nurix Therapeutics Inc. (NRIX) stock has fallen to a 52-week low of $13.64, marking a 52% decrease from its high of $28.23. Despite this downturn and a recent 9.6% drop, InvestingPro data suggests the stock is trading below its Fair Value and is in oversold territory, potentially signaling a rebound. Analysts have mixed views, with some raising price targets following strong Q3 fiscal 2026 results, while others lowered targets due to a discontinued Sanofi program.
NRIX: Bexdeg advances in CLL, with 2027 enrollment forecasts and combination data ahead
Nurix Therapeutics (NRIX) is expected to present an update on Bexdeg at ASH, showing an ~85% overall response rate and 22.1-month progression-free survival in advanced chronic lymphocytic leukemia. The company plans for phase III enrollment by 2027 and is advancing combination and immunology strategies. Additionally, the Gilead IRAK4 program is nearing a phase II decision.
NRIX: Bexdeg's phase III tests degradation against pirtobrutinib as pipeline catalysts broaden
Nurix Therapeutics' drug Bexdeg is progressing in second and third-line+ Chronic Lymphocytic Leukemia (CLL), supported by a Phase III head-to-head trial, combination therapies, and CNS activity. Upcoming updates in 2027 are expected to include trial enrollment figures, autoimmune disease plans, CBL-B data, and details on Gilead's IRAK4 program. This information was based on Nurix Therapeutics, Inc.'s UBS Global Biopharma Conference 2026 Audio Transcript.
One fund holds the 5.37 million Nurix Therapeutics (NRIX) shares reported by three parties.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. collectively reported beneficial ownership of 5,371,629 common shares, representing a 4.9% stake in Nurix Therapeutics, Inc. The shares are directly held by the Master Fund, while Perceptive Advisors and Joseph Edelman are deemed beneficial owners due to their roles as investment manager and managing member, respectively. This disclosure is based on 109,249,814 shares outstanding as of September 30, 2026.
T. Rowe Price Updates 4.4% Stake Disclosure in Nurix Therapeutics
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a 4.4% beneficial ownership in Nurix Therapeutics Inc. as of September 30, 2026. The investment adviser holds 4,570,774 shares, with sole voting power over 4,422,815 shares and sole dispositive power over all disclosed shares. This filing confirms T. Rowe Price's ownership remains below the 5% threshold, stating the acquisition was in the ordinary course of business and not for influencing control of the issuer.
T. Rowe Price reports 4.57 million Nurix Therapeutics (NRIX) shares, below the 5% mark.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G/A, reporting a 4.4% stake in Nurix Therapeutics, Inc. (NRIX) as of September 30, 2026. The firm beneficially owned 4,570,774 shares, with sole voting power over 4,422,815 shares and sole dispositive power over all 4,570,774 shares. T. Rowe Price explicitly denied beneficial ownership and indicated its stake was below the 5% threshold, acquired in the ordinary course of business.
Three reporting owners share a 6 million-share passive stake in Nurix Therapeutics (NRIX).
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have each reported a beneficial ownership of 6,000,000 common shares in Nurix Therapeutics (NRIX), representing a 5.49% stake. This information was disclosed in an amended SCHEDULE 13G/A filing with the SEC on November 16, 2026. The reporting persons share voting and dispositive power over these shares, which are not additive in their reported positions.
Nurix Therapeutics (NRIX) Could Be 55% Undervalued After Sanofi Ends Phase 1 Program
Nurix Therapeutics (NRIX) shares are under pressure after Sanofi ended its Phase 1 trial for a key candidate, impacting potential future milestones and royalties. Despite recent stock declines, analysts on Simply Wall St believe Nurix is materially undervalued with a fair value of $34.50, significantly higher than its current trading price of $15.48, largely due to its collaboration with Roche for bexobrutideg. However, risks remain regarding clinical trial outcomes and high R&D spending.
The Technical Signals Behind (NRIX) That Institutions Follow
This article analyzes Nurix Therapeutics Inc. (NASDAQ: NRIX), highlighting positive near-term sentiment amidst a weak mid-term and strong long-term context. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop levels. The analysis also details multi-timeframe signal strengths, support, and resistance levels for NRIX.
Nurix Therapeutics stock is up, what you need to know
Shares of Nurix Therapeutics (NRIX) rose 3.4% following the appointment of Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development for the company's protein degradation pipeline, including a key BTK degrader partnered with Roche. This news is considered meaningful by the market, although the stock remains volatile and is down 9.4% year-to-date, trading significantly below its 52-week high.
Arati V Rao named chief medical officer by Nurix Therapeutics
Nurix Therapeutics has appointed Arati V Rao, M.D., as its new chief medical officer. Dr. Rao brings over two decades of experience in global clinical development and regulatory submissions to the role. She will be responsible for leading the company's clinical development programs and enhancing its operational and regulatory capabilities.
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Nurix Therapeutics has appointed Arati V. Rao, M.D., as its new Chief Medical Officer. Dr. Rao brings over two decades of experience in academic medicine, global clinical development, and regulatory submissions, particularly in hematologic malignancies. She will lead Nurix's clinical development, advancing its registrational program for bexobrutideg and other pipeline initiatives.
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that its management will participate in fireside chats at three upcoming investor conferences: the UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and Piper Sandler Annual Healthcare Conference, all in November and December 2026. These webcasts will be available live on the Investors section of Nurix's website and archived for 30 days. The company, a clinical-stage biopharmaceutical firm, focuses on targeted protein degradation medicines for cancer and autoimmune diseases, with an oncology pipeline including bexobrutideg and NX-1607.
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that its management will participate in three upcoming investor conferences: the UBS Global Biopharma Conference, the Jefferies Global Healthcare Conference, and the Piper Sandler Annual Healthcare Conference, all in November and December 2026. The company, a clinical-stage biopharmaceutical firm, will feature fireside chats at these events, which will be webcast live and archived on its investor website. Nurix focuses on developing targeted protein degradation medicines for cancer and autoimmune diseases.
Three Nurix investor chats will be webcast and archived for 30 days.
Nurix Therapeutics (NRIX) announced its management will participate in three upcoming investor conferences: the UBS Global Biopharma Conference, the Jefferies Global Healthcare Conference, and the Piper Sandler Annual Healthcare Conference. Live webcasts of these fireside chats will be available on Nurix’s Investors section, with archives accessible for 30 days following each event. The company is a clinical-stage biopharmaceutical firm focused on targeted protein degradation medicines for cancer and autoimmune diseases.
Nurix Therapeutics, Inc. $NRIX Shares Sold by Sumitomo Mitsui Trust Group Inc.
Sumitomo Mitsui Trust Group Inc. reduced its stake in Nurix Therapeutics (NASDAQ:NRIX) by 12.2% in the third quarter, selling 120,385 shares, while still holding 863,077 shares worth approximately $20.5 million. Conversely, other institutional investors like BlackRock and Dimensional Fund Advisors increased their holdings. Nurix Therapeutics' stock was down 7.0% at $14.84, despite analysts maintaining a "Moderate Buy" consensus with an average price target of $34.43 and the company beating quarterly earnings estimates.
An experimental blood cancer drug showed high response rates in previously treated patients.
Nurix Therapeutics will present updated data for its investigational drug, bexobrutideg (NX-5948), at the 68th ASH Annual Meeting in December 2026. The Phase 1a/1b trial showed high response rates, durable clinical activity, and favorable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with covalent BTK inhibitors. The company is encouraged by the drug's potential to address unmet needs and target both wild-type and mutant forms of BTK.
Form 4 Nurix Therapeutics Inc: Hans van Houte (CFO) For: 4 November By Investing.com
This article reports a Form 4 filing for Nurix Therapeutics Inc., indicating an insider transaction by Chief Financial Officer Hans van Houte on November 4th. The filing is provided by Investing.com, a financial markets news and data platform.
Sanofi Decides to Stop Studies of Nurix-Partnered Experimental Drug
Sanofi has decided to halt studies on an experimental inflammatory disease therapy developed in partnership with Nurix Therapeutics. This news led to an extended decline in Nurix Therapeutics' shares, which continued from Tuesday's market close into Wednesday's premarket trading. The decision impacts the future development of the drug.
A 4,769-share sale is proposed by Nurix Therapeutics (NRIX) officer Johannes van Houte.
Nurix Therapeutics (NRIX) officer Johannes van Houte has proposed selling 4,769 common shares, valued at approximately $123,135.58, with an approximate sale date of November 4, 2026. The SEC Form 144 filing also indicates that van Houte sold 2,834 common shares for $74,474.97 in the preceding three months and acquired 4,769 common shares from the issuer as restricted stock units on October 30, 2026. Morgan Stanley Smith Barney LLC is listed as the broker for the proposed sale on NASDAQ.
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Down After Analyst Downgrade
Nurix Therapeutics (NASDAQ:NRIX) shares gapped down following Wells Fargo & Company lowering its price target from $25 to $20, although maintaining an "overweight" rating. This downgrade comes after Sanofi discontinued a partnered Phase 1 trial for a STAT6 degrader, SAR448272. Despite this setback and recent insider sales, the consensus analyst rating remains a "Moderate Buy" with an average target price of $34.43.
Form 144 NURIX THERAPEUTICS For: 4 November By Investing.com
This article reports on a Form 144 filing by NURIX THERAPEUTICS for November 4, 2026. Form 144 filings typically indicate an insider's intent to sell restricted or controlled securities. The article provides the basic announcement without further details on the transaction.
Why Nurix Therapeutics (NRIX) stock is down today
Nurix Therapeutics's stock fell 39.8% after collaboration partner Sanofi discontinued the Phase 1 study of oral STAT6 degrader SAR448272, ending future payments and royalties from the program. Despite the setback, Nurix stated that its cash and marketable securities of $1.1 billion as of August 31 are sufficient to fund operations into the second half of 2029. The news significantly impacted market perception, with the stock trading 43% below its 52-week high.
A 6,113-share sale is proposed by Nurix Therapeutics (NRIX) officer Christine Ring.
Christine Ring, an officer at Nurix Therapeutics (NRIX), has proposed selling 6,113 common shares with an aggregate market value of $157,104.10, according to a recent Form 144 SEC filing. The proposed sale is being handled by Morgan Stanley Smith Barney LLC and relates to restricted stock units acquired on October 30, 2025. The filing also disclosed four previous Rule 10b5-1 sales by Ring between September and November 2026.
NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
Shares of Nurix Therapeutics, Inc. (NRIX) dropped 35% after hours following the announcement that its partner Sanofi (SNY) has discontinued the development of the experimental oral drug SAR448272. This decision eliminates potential milestone payments and royalties specifically for this program, though Nurix remains eligible for payments on other licensed programs with Sanofi. Despite the setback, Nurix stated that its cash runway guidance remains unchanged, projecting funding into the second half of 2029 with $1.1 billion in cash and equivalents.
Nurix Shares Drop 35% After Sanofi Scraps Oral Immunology Drug
Nurix Therapeutics saw its shares drop about 35% after its partner Sanofi discontinued the development of SAR448272, an early-stage oral STAT6 degrader for atopic dermatitis and asthma. This decision removes approximately $455 million in potential milestone payments. Despite the setback, Nurix maintains a strong cash position of $1.1 billion, expected to fund operations into the second half of 2029, and its lead asset, bexobrutinib, is in Phase 3 testing with Roche.
Nurix says Sanofi discontinues autoimmune disease drug program
Nurix Therapeutics announced that Sanofi has discontinued the development of SAR448272, an experimental treatment for autoimmune and inflammatory diseases, leading to a plunge in Nurix's shares. This decision eliminates potential future milestone payments and royalties related to this specific program. Despite this setback, Nurix stated it remains eligible for payments from other drug candidates under its collaboration with Sanofi and expects its cash reserves to fund operations into the second half of 2029.
Nurix Therapeutics stock tumbles on Sanofi program termination
Nurix Therapeutics Inc. (NASDAQ:NRIX) shares plummeted 34% after-hours following Sanofi’s decision to halt the development of SAR448272, an oral STAT6 degrader, and terminate its associated clinical trial. This decision eliminates Nurix's eligibility for future milestone payments and royalties for SAR448272, though it retains rights to other programs under its collaboration with Sanofi. Despite the program's termination, Nurix affirmed its cash runway guidance, stating it has sufficient funds to operate into the second half of 2029, and continues to advance three other clinical-stage programs.
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
Nurix Therapeutics announced that Sanofi has decided to discontinue the development of SAR448272, an oral STAT6 degrader, and terminate its associated program. This decision means Nurix will not receive future milestone payments or royalties for this specific program. However, Nurix's other partnered programs with Sanofi and its wholly owned pipeline remain active, and the company maintains a strong cash runway extending into the second half of 2029.
NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
Nurix Therapeutics (NRIX) shares dropped 35% after Sanofi announced it is discontinuing development of the experimental oral drug SAR448272, which it had licensed from Nurix. This decision eliminates potential milestone payments and royalties for Nurix specific to this program. Despite the setback, Nurix stated it remains eligible for payments on other partnered programs and maintains a strong cash runway expected to fund operations into the second half of 2029.
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 3,957 Shares of Stock
Gwenn Hansen, an insider at Nurix Therapeutics (NASDAQ:NRIX), sold 3,957 shares of the company's stock for approximately $104,000 to cover tax withholding obligations related to vested equity awards. This sale, executed under a pre-arranged Rule 10b5-1 trading plan, reduced Hansen's direct ownership by 3.11%, though she still retains 123,452 shares. The company recently reported strong quarterly earnings and revenue, significantly exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating from Wall Street with an average price target of $34.79.
Form 4 Nurix Therapeutics Inc: Christine Ring (CLO) For: 30 October
This article reports on a Form 4 filing for Nurix Therapeutics Inc., indicating a transaction by Christine Ring, the company's Chief Legal Officer (CLO), on October 30. Form 4 filings are mandatory reports that must be submitted to the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article provides the basic information about the filing and the individual involved.
Form 4 Nurix Therapeutics Inc: Gwenn Hansen (Chief Scientific Officer) For: 30 October
This article reports on a Form 4 filing for Nurix Therapeutics Inc., detailing a transaction made by Gwenn Hansen, the Chief Scientific Officer, on October 30th. Form 4 filings are regulatory documents used to disclose changes in beneficial ownership of securities by a company's insiders. The specific details of the transaction are not provided within this brief report.
Officer Christine Ring proposes selling 10,602 Nurix Therapeutics (NRIX) shares.
Christine Ring, an officer at Nurix Therapeutics, has proposed selling 10,602 common shares of NRIX, valued at approximately $284,133.60, with an approximate sale date of November 2, 2026. This notice also details four prior sales under a Rule 10b5-1 plan between August and October 2026. The proposed sale involves shares acquired through the exercise of stock options and vesting of restricted stock units.
Avoiding Lag: Real-Time Signals in (NRIX) Movement
Nurix Therapeutics Inc. (NASDAQ: NRIX) shows strong sentiment across all horizons, supporting an overweight bias with an exceptional 54.7:1 risk-reward setup. AI models have generated distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles and holding periods, incorporating sophisticated risk management parameters. The analysis highlights key support and resistance levels across near-term, mid-term, and long-term horizons, indicating strong signals for all.
Nurix Therapeutics, Inc. (NRIX) Seasonal returns chart
This article provides a seasonality chart for Nurix Therapeutics, Inc. (NRIX), displaying average monthly price returns from 2020 to 2026. The stock's current real-time price on NasdaqGM is also shown, along with its performance at close and after hours on October 30.
Nurix Therapeutics, Inc. Estimates – NASDAQ:NRIX
This article from TradingView provides an overview of Nurix Therapeutics, Inc. (NASDAQ: NRIX) financial data and analyst estimates. It allows users to explore reported financials and compare them against average, high, and low estimates, visualizing trends over time across income statements, balance sheets, and cash flow statements. The content focuses on presenting financial information without offering investment advice.
Nurix stock: H.C. Wainwright raises target for Nurix stock to USD 36.00
H.C. Wainwright increased its price target for Nurix Therapeutics (NRIX) stock from USD 34.00 to USD 36.00, maintaining a Buy rating. This adjustment follows Nurix's strong fiscal third-quarter results, which included USD 673.1 million in collaboration and license revenue and a net income of USD 549.8 million, primarily driven by its Roche collaboration. The company's substantial cash balance of USD 1.1 billion is expected to fund operations into the second half of 2029, supporting ongoing clinical programs.
Weekly Recap: Q3 Roche $653.2M license lift and NX-5948 pivotal dosing
Nurix Therapeutics, Inc. (NRIX) reported strong Q3 2026 results, including $673.1M in revenue and $549.8M in net income, largely due to a $653.2M Roche license payment. The company also initiated a pivotal trial for NX-5948, broadened the development of bexobrutideg for immune diseases, and received milestone payments from Sanofi and Pfizer. NRIX now projects its cash runway to extend into the second half of 2029.
Nurix Therapeutics 3Q 2026: Revenue $673.1M, EPS $4.73— 10-Q Summary
Nurix Therapeutics reported a strong third quarter in 2026, with revenue reaching $673.1M and net income at $549.8M, a significant increase year-over-year largely due to license revenue from Roche. Diluted EPS was $4.73. The company also highlighted clinical advancements for bexobrutideg and NX-1607, expanded partnerships, and strategic pipeline prioritization.
Nurix Therapeutics (NASDAQ:NRIX) Upgraded to Buy at Wall Street Zen
Nurix Therapeutics (NASDAQ:NRIX) has been upgraded to a "buy" rating by Wall Street Zen, contributing to a "Moderate Buy" consensus among analysts with an average price target of $34.79. The upgrade follows Nurix's strong quarterly earnings report, where it significantly beat analyst estimates for both EPS and revenue. Despite recent insider selling, institutional investors have shown increased interest by initiating or expanding their positions in the company.
Nurix Therapeutics CSO Gwenn Hansen sells $36,300 in common stock
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NASDAQ:NRIX), sold 1,452 shares of company stock worth $36,300 after exercising employee stock options. Despite the sale, Ms. Hansen directly owns 117,227 shares, and the company's stock has surged 149% over the past year, with analysts adjusting price targets upwards following recent earnings. InvestingPro analysis indicates the stock is undervalued with an "EXCELLENT" financial health score.
Nurix Therapeutics (NRIX) Could Be 20% Below Fair Value After Roche Fueled Profit Turn
Nurix Therapeutics (NRIX) has returned to focus after a profitable fiscal third quarter, driven by a large Roche collaboration payment and progress in its bexobrutideg program, leading to significant share price momentum. The company is perceived to be undervalued by approximately 20% against an implied fair value of $25.00, with its valuation dependent on the successful progression of its late-stage programs and partnerships with major pharmaceutical companies. However, risks such as slowed trials or high development costs could impact its valuation.
Form 4 Nurix Therapeutics Inc: Gwenn Hansen (Chief Scientific Officer) For: 15 October
This article reports on a Form 4 filing for Nurix Therapeutics Inc., indicating an insider transaction involving Gwenn Hansen, the Chief Scientific Officer, on October 15. Form 4 filings are regulatory documents disclosing changes in ownership of company stock by insiders. The article also provides the stock market data for NRIX, showing a slight decrease.
Form 4 Nurix Therapeutics Inc: Gwenn Hansen (Chief Scientific Officer) For: 15 October By Investing.com
This article reports a Form 4 filing for Nurix Therapeutics Inc, specifically detailing an insider transaction by Gwenn Hansen, the Chief Scientific Officer, for October 15. The brief announcement, published by Investing.com, indicates the disclosure of stock-related activities by a key executive at the company.
Nurix advances bexobrutideg: Stifel raises target for Nurix Therapeutics stock
Nurix Therapeutics (NRIX) has reported strong fiscal third-quarter results with revenue of USD 673.1 million, driven largely by collaborations with Roche and Sanofi. The company also announced the advancement of its drug candidate bexobrutideg into Phase 3 clinical trials for CLL and SLL. Following these developments, Stifel has raised its price target for Nurix Therapeutics stock from USD 40.00 to USD 41.00, maintaining a Buy rating.
Nurix Therapeutics CSO Gwenn Hansen sells $36,300 in common stock By Investing.com
Gwenn Hansen, CSO of Nurix Therapeutics (NASDAQ:NRIX), sold 1,452 shares of common stock for $36,300 on October 15, 2026, following the exercise of employee stock options. The sale was executed at $25.00 per share under a Rule 10b5-1 plan, leaving her with 117,227 direct shares. Concurrently, she acquired 1,452 shares by exercising options at $1.86 per share, totaling $2,700.
Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 1,452 Shares of Company Stock
Nurix Therapeutics insider Gwenn Hansen recently sold 1,452 shares of the company's stock for $36,300, reducing her holdings by 1.22% under a pre-arranged Rule 10b5-1 plan. Despite this insider selling and other similar transactions, Nurix reported strong quarterly earnings, significantly exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating with an average price target of $34.64. The company also initiated a Phase 3 trial for bexobrutideg, contributing to broadly positive analyst sentiment.
Nurix Therapeutics’ High-Stakes Reliance on Roche: Cost Burdens, Control Risks and Uncertain Returns for Lead Drug Bexobrutideg
Nurix Therapeutics (NRIX) faces significant dependency risk due to its collaboration with Roche for its lead drug, bexobrutideg. The agreement places substantial financial burdens on Nurix, requiring it to fund 40% of development costs and share in U.S. profits and losses, while granting Roche primary control over key decisions. This arrangement could strain Nurix's resources and limit its influence over the drug's commercial trajectory and financial returns, with potential adverse consequences if the collaboration were to be altered or terminated.
Form 4 Nurix Therapeutics Inc: Julia P. Gregory (Director) For: 14 October
This article reports on a Form 4 filing for Nurix Therapeutics Inc., indicating an insider transaction by director Julia P. Gregory. The filing date mentioned is October 14. The article primarily serves as a brief financial market update regarding insider trading activity.